TELA Bio, Inc. (TELA): Results of Operations and Financial Condition
TELA Bio, Inc. (TELA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 tm2622768d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 TELA Bio Reports Second Quarter 2026 Financial Results MALVERN, PA, August 10, 2026 -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction
How this was made
The 30-second read
Why it matters
The key tradable disclosure is the withdrawal of full-year 2026 revenue guidance, attributed to OviTex PRS volume declines and ongoing price and mix headwinds, with management signaling cost structure alignment to extend cash runway.
Market read
Investors must reprice TELA’s forward revenue expectations due to the guidance withdrawal and the disclosed Q2 drivers, while monitoring whether PRS performance and ASP/mix stabilize in 2H.
What to watch
Gross margin improved to 72% (tariff refund and lower excess/obsolete charges), and cash was $30.4M at June 30, 2026, which could reduce immediate dilution fears if cost actions are credible.
Background
TELA Bio reported Q2 2026 results and announced a new CEO (Heather Getz) effective August 4, 2026, alongside a strategic sales-structure change.
Ticker impact
TELA withdrew full-year 2026 revenue guidance after Q2 revenue fell to $19.3M, driven by lower OviTex PRS volumes and price/mix headwinds.
Likely downside bias and elevated volatility until management updates full-year outlook and PRS performance stabilizes.
The filing discloses a concrete guidance withdrawal plus Q2 underperformance drivers (OviTex PRS volume decline, price/mix headwinds) and cost alignment intent, which typically pressures valuation multiples for commercial-stage medtech.
Market effects
Soft-tissue reconstruction peers may face read-across risk if investors interpret PRS volume weakness as demand or competitive share pressure.
International revenue grew 26% YoY, which may partially offset concerns about Europe versus US procedure dynamics.
Limited broader market impact; primarily company-specific sentiment for small-cap medtech.
Counterpoint
International growth (26% YoY) and OviTex unit volume growth for OviTex (12% for OviTex unit volume) suggest underlying demand and share gains may be real, with the guidance withdrawal reflecting timing rather than structural deterioration.
Key entities
- companyTELA Bio, Inc.
Commercial-stage medical technology company reporting Q2 2026 financial results and withdrawing full-year 2026 guidance.
- executiveHeather Getz
Appointed CEO and Director effective August 4, 2026; cited PRS performance issues and competitive bundling dynamics.
